Raymond James Downgrades Teva Pharmaceutical Indus to Market Perform
Raymond James analyst Elliot Wilbur downgrades Teva Pharmaceutical Indus (NYSE:TEVA) from Outperform to Market Perform.
Looking Into Teva Pharmaceutical Indus’s Return On Capital Employed
Pulled from Benzinga Pro data, Teva Pharmaceutical Indus (NYSE:TEVA) posted Q3 earnings of $623.00 million, an increase from Q2 of 7.04%. Sales dropped to $3.89 billion, a 0.59% decrease between quarters.
Teva Q3 Earnings Fall Short Of Expectations; Reaffirms FY21 Guidance
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Q3 sales
Teva Pharmaceutical Indus Q3 Adj. EPS $0.59 Misses $0.65 Estimate, Sales $3.89B Miss $4.03B Estimate; Reaffirms Guidance
Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.59 per share which missed the analyst consensus estimate of $0.65 by 9.23 percent. This is a 1.72 percent increase over earnings of $0.58 per share
Earnings Scheduled For October 27, 2021
Companies Reporting Before The Bell
• McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion.
10 Health Care Stocks With Unusual Options Alerts In Today’s Session
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels.
Bitcoin Is The Ferrari And Gold Is The Horse And Buggy, According To Bill Miller
Legendary value investor Bill Miller remains bullish on Bitcoin (CRYPTO: BTC) and continues to add to his position.